Cassava Sciences Inc vs iShares Gold Trust — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while iShares Gold Trust trades at $82.87. The key difference: iShares Gold Trust is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | IAU | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $4.64 | $101.57 |
52-Week Low | $0.87 | $62.49 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
IAU (iShares Gold Trust) trades at $82.76, up 0.3% on the day, with technical indicators showing mixed signals - a bullish moving average trend but overbought RSI levels. The ETF benefits from gold's recent momentum as inflation data aligns with expectations and geopolitical tensions boost safe-haven demand. Recent news highlights gold's strong performance with spot prices reaching $4,438/oz following July CPI data.
The outlook remains positive given gold's defensive characteristics amid economic uncertainty, though overbought technical conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy shifts and dollar strength, while institutional buying and central bank demand provide underlying support.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →